Rapamune and Digoxin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Rapamune (sirolimus) and Digoxin (digoxin). Common drug interactions include anhedonia among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Rapamune and Digoxin. It is created by eHealthMe based on reports of 91 people who take the same drugs from the FDA, and is updated regularly.

What is Rapamune?

Rapamune has active ingredients of sirolimus. It is often used in kidney transplant. eHealthMe is studying from 13,848 Rapamune users. Check the latest studies of Rapamune.

What is Digoxin?

Digoxin has active ingredients of digoxin. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 93,740 Digoxin users. Check the latest studies of Digoxin.



On Aug, 01, 2026

91 people who take Rapamune and Digoxin together, and have interactions are studied.

Rapamune and Digoxin drug interactions.

What are the common drug interactions of Rapamune and Digoxin, by gender? *:

female:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Cardiac failure
  4. Cerebral infarction (less blood supply to brain resulting tissue damage)
  5. Depression
  6. Dyspnoea (difficult or laboured respiration)
  7. Emotional distress
  8. Fear
  9. Injury
  10. Multi-organ failure (multisystem organ failure)

male:

  1. Drug ineffective
  2. General physical health deterioration (weak health status)
  3. Hypertension (high blood pressure)
  4. Pain
  5. Renal failure acute (rapid kidney dysfunction)
  6. Renal failure chronic (long lasting kidney dysfunction)
  7. Anaemia (lack of blood)
  8. Dementia (madness)
  9. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  10. Hypotension (abnormally low blood pressure)

What are the common drug interactions of Rapamune and Digoxin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Operative haemorrhage (bleeding due to surgery)

20-29:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Death
  4. Depression
  5. Emotional distress
  6. Fear
  7. Injury
  8. Multi-organ failure (multisystem organ failure)
  9. Pain
  10. Renal failure (kidney dysfunction)

30-39:

  1. Acute respiratory distress syndrome
  2. Blood creatinine increased
  3. Candidal infection (fungal infection)
  4. Cardiomegaly (increased size of heart than normal)
  5. Disseminated intravascular coagulation (systemic activation of blood coagulation)
  6. Haemoglobin s decreased
  7. Multi-organ failure (multisystem organ failure)
  8. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  9. Neutrophilia
  10. Pallor

40-49:

  1. Cardiac failure
  2. Cardiomegaly (increased size of heart than normal)
  3. Cerebral infarction (less blood supply to brain resulting tissue damage)
  4. Muscle weakness (a lack of muscle strength)
  5. Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
  6. Pneumonia
  7. Post procedural haemorrhage (post procedural bleeding)
  8. Pulmonary haemorrhage (acute bleeding from the lung)
  9. Pulmonary oedema (fluid accumulation in the lungs)
  10. Respiratory failure (excl neonatal) (inadequate gas exchange by the respiratory system(excluding neonatal))

50-59:

  1. Erythema (redness of the skin)
  2. General physical health deterioration (weak health status)
  3. Joint range of motion decreased (disease of joint movement)
  4. Joint stiffness
  5. Mobility decreased (ability to move is reduced)
  6. Muscular weakness (muscle weakness)
  7. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)
  8. Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
  9. Pain
  10. Scar

60+:

  1. Drug ineffective
  2. Dyspnoea (difficult or laboured respiration)
  3. General physical health deterioration (weak health status)
  4. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  5. Hypotension (abnormally low blood pressure)
  6. Loss of consciousness
  7. Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
  8. Nausea (feeling of having an urge to vomit)
  9. Renal failure acute (rapid kidney dysfunction)
  10. Renal failure chronic (long lasting kidney dysfunction)

What are the existing conditions these people have? *

  1. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 7 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Rapamune and Digoxin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Rapamune and Digoxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rapamune:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Digoxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rapamune and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Digoxin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on sirolimus and digoxin (the active ingredients of Rapamune and Digoxin, respectively), and Rapamune and Digoxin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: